Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6”In the company’s words, NCT05845840 on ClinicalTrials.gov
- Tested for
- Postpartum Depression
- Main trialPhase 1
- “The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of BRII-297 in healthy adult subjects. The main aim of the study is to evaluate the safety and tolerability after single dose intramuscular administration of BRII-297. The study also aims at characterizing the PK profiles of BRII-297 and brexanolone after single dose intramuscular administration. Participants will be enrolled in 6 cohorts (3 planned and 3 optional) with 6 participants per cohort \[(4 active: 2 placebo) - Cohorts 1 \& 2\] and 10 participants per cohort \[(8 active: 2 placebo) -…”In the company’s words, NCT05845840 on ClinicalTrials.gov
Other drugs for Postpartum Depression
- LPCN 1154ALipocine Inc. · Phase 3
- MI078Nanjing Minova Pharmaceutical Co., Ltd. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 21 Nov 2023 | A Study of BRII-297 in Healthy Adult Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026